Get the tools used by (smart)2 investors.
SP500 0.1%DOW 0.3%FTSE 100 0.1%NIKKEI 0.5%OIL -1.8%GOLD 1.4%
Sign In
WatchlistsIdeasScreenerData ExplorerChartsSaved Work

Unlevered Free Cash Flow for CytomX Therapeutics Inc

Join now and get access to the full platform

Search for company or ETF

 

  0 results available. Select is focused ,type to refine list, press Down to open the menu,

CTMX: CytomX Therapeutics Inc

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The comp...

0.71 USD
Price
– USD
Fair Value
–
Upside
0.40 - 5.85
52-week range
Create ChartCreate ModelAdd To Watchlist

Analysis

Fiscal Years
Trailing Twelve Months
Fiscal Halfs
Fiscal Quarters
Daily
Hide this widget

The following section summarizes insights on CytomX Therapeutics Inc's Unlevered Free Cash Flow:

Dec 2016Dec 2018Dec 2020Dec 2022Dec 2024-150 M-100 M-50 M0 K
Performance Summary
  • CytomX Therapeutics's latest twelve months unlevered free cash flow is -45.998 million
  • CytomX Therapeutics's unlevered free cash flow for fiscal years ending December 2020 to 2024 averaged -46.125 million.
  • CytomX Therapeutics's operated at median unlevered free cash flow of -45.998 million from fiscal years ending December 2020 to 2024.
  • Looking back at the last 5 years, CytomX Therapeutics's unlevered free cash flow peaked in December 2023 at 33.582 million.
  • CytomX Therapeutics's unlevered free cash flow hit its 5-year low in December 2020 of -87.568 million.
  • CytomX Therapeutics's unlevered free cash flow decreased in 2024 (-45.998 million, -237.0%) and increased in 2020 (-87.568 million, -35.4%), 2021 (-86.544 million, -1.2%), 2022 (-44.098 million, -49.0%), and 2023 (33.582 million, -176.2%).

How does CytomX Therapeutics Inc's Unlevered Free Cash Flow benchmark against competitors?

Hide this widget

We've identified the following companies as similar to CytomX Therapeutics Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.

CytomX Therapeutics Inc Unlevered Free Cash Flow Benchmarks
NameTickerUnlevered Free Cash Flow
Geron CorporationNASDAQGS:GERN-199.2 M
HealthcareNASDAQGM:ARCT-69.488 M
Spruce Biosciences IncNASDAQCM:SPRB-57.104 M
CytomX Therapeutics IncNASDAQGS:CTMX-45.998 M
Caredx IncNASDAQGM:CDNA-40.262 M
Cardiff Oncology IncNASDAQCM:CRDF-39.266 M
Trevena IncPINC:TRVN-25.113 M
HealthcareSECTOR:HLTH.US-11.57 M
Aditx Therapeutics IncNASDAQCM:ADTX-9.49 M
Onconetix IncNASDAQCM:ONCO-7.358 M
Dyadic International IncNASDAQCM:DYAI-4.626 M
ADMA Biologics IncNASDAQGM:ADMA102.3 M

Metric Usage: Unlevered Free Cash Flow

Hide this widget
fcf_unlev
Slug
number
Datatype
text
Format
current
Default Period
FY, Q, LTM
Periods Supported
Free
Plan

To view the full list of supported financial metrics please see Complete Metrics Listing.

Similar Metrics

Hide this widget

Metrics similar to Unlevered Free Cash Flow in the financials category include:

  • Unadjusted EBITDA - Unadjusted income before interest, taxes, depreciation and amortization.
  • Diluted EPS (Cont. Ops) - Company's net earnings or losses from continuing operations on a per diluted share basis.
  • Other Operating Expenses, Total - This item represents the other operating costs incurred during the given fiscal year.
  • NCAV Per Share - A calculation inspired by Benjamin Graham. Net Current Asset Value is calculated as current assets minus total liabilities. NCAV per share expresses this calculation on a per share basis.
View Full List

Search for metric or datapoint

Unlevered Free Cash Flow

A cash flow measure that represents cash available to all providers of capital, including debt, equity, and hybrid capital. It is used to remove the i...

Definition of Unlevered Free Cash Flow

Hide this widget

The Unlevered Free Cash Flow is calculated as follows:

EBIT
(x) (1 - Marginal Tax Rate)
(=) NOPAT
(+) Depreciation and Amortization
(-) Capital Expenditures
(-) Investment in Net Working Capital
(=) Unlevered Free Cash Flow

Read more about nopat, depreciation & amortization, capital expenditures, and net working capital

Click the link below to download a spreadsheet with an example Unlevered Free Cash Flow calculation for CytomX Therapeutics Inc below:

Sector Benchmark Analysis

All rights reserved. Terms Of Use